This high-impact role will shape Alumis's expanding clinical portfolio from the ground up, from indication selection and study design through proof-of-concept readout, and will serve as a key scientific leader and external face of the program with investigators, regulatory authorities, and the broader medical community. Experience across multiple therapeutic indications, including neurological diseases (e.g., neurodegenerative diseases, movement disorders) and/or inflammatory conditions such as psoriasis, psoriatic arthritis, lupus, or atopic dermatitis.